What were the key takeaways from Bioatla’s earnings call?

What is the revenue and EPS growth rate for Bioatla year over year?

What guidance did Bioatla's management provide for the next earnings period?

What does Bioatla do and what are its main business segments?

What were the key takeaways from Bioatla's earnings call?

What is Bioatla's latest dividend and current dividend yield?

What is Bioatla's gross profit margin?

Did Bioatla beat or miss consensus estimates last quarter?

- **Strategic Momentum**: Imminent Phase III trial initiation for Oz-V in OPSCC with $800M peak sales potential.
- **Clinical Success**: BA3182 shows tumor control across 8 adenocarcinoma types; Mec-V OS doubles current standards.
- **Financial Resilience**: $2M milestone payment offsets $15.8M net loss; R&D/G&A expenses down 69%/29%.
- **Upcoming Milestones**: Oz-V interim analysis H2 2025; BA3182 data readout H1 2026.

**【CEO Summary Section】**
- BioAtla nearing completion of a strategic transaction with a potential partner by year-end.
- FDA alignment on Phase III Oz-V trial design for second-line OPSCC with dual primary endpoints: overall response rate and overall survival.
- BA3182 Dual-CAB EpCAM TCE shows manageable safety profile and tumor control in multiple adenocarcinoma types.
- Mec-V demonstrates 21.5-month median OS in soft tissue sarcoma, superior to current standards.
- $2M milestone payment received from Context Therapeutics for Dual-CAB Nectin-4 TCE program.

**【CFO Financial Commentary】**
- Cash and cash equivalents: $8.3 million as of September 30, 2025.
- Net loss of $15.8 million (Q3 2025) vs. $10.6 million (Q3 2024), driven by reduced collaboration revenue and cost reductions.
- R&D expenses down 69% to $9.5 million (Q3 2025) due to program prioritization and workforce reduction.
- G&A expenses down 29% to $4.2 million (Q3 2025) from lower personnel costs.

**【Q&A Highlights】**
- Oz-V Phase III trial requires ~300 patients for full approval, with interim analysis for accelerated approval.
- Control arm stratified by p16 status and regional disease distribution.
- BA3182 expected to report additional dose/schedule data in H1 2026.
- Mec-V safety profile consistent with AXL target restriction to tumor microenvironment.

BioAtla, Inc. (BCAB) Q3 2025 Earnings Call Transcript

- **BA3182 Shows Promise**: 7 patients achieved tumor reductions; Phase I data expected Q4 2025. Potential for 1M+ solid tumor patients.
- **Oz-V FDA Support**: Pivotal Phase III trial design agreed; ORR 45% vs 3.4% for SOC. Targeting accelerated approval.
- **Strong Cash Management**: Q2 cash burn $14.1M; expects reduced burn as trials complete. $18.2M cash as of June 30, 2025.
- **Partnership Momentum**: Term sheet signed for Phase II asset; expects transaction Q4 2025.

**【CEO Opening Remarks】**
- **BA3182 Progress**: Phase I interim data shows 7 patients (across colon, breast, bile duct, lung, and pancreas cancers) achieved tumor reductions. Cohort 1.2mg is dosing, with Phase I data expected Q4 2025 and expansion data Q1 2026. Potential for 1M+ patients across solid tumors.
- **Oz-V Update**: FDA supports pivotal Phase III trial in HPV+ oropharyngeal SCC, with dual primary endpoints (ORR, OS). ORR 45% vs 3.4% for SOC; OS 11.6m vs 4.4m. Targeting accelerated approval.
- **Pipeline Strength**: Mec-V (CAB-AXL-ADC) shows 67% 1-year survival in mKRAS NSCLC; evalstotug (CAB-CTLA4) active in melanoma post-PD1/LAG3. 
- **Corporate Updates**: NASDAQ compliance plan in progress; abstract accepted for ESMO 2025. Partnering discussions advanced, with term sheet for one Phase II asset.

**【CFO Financial Commentary】**
- **R&D Expenses**: $13.7M (Q2 2025) vs $16.2M (2024), down 15% due to workforce reduction ($1.2M), program prioritization ($0.6M), and lower stock comp ($0.6M).
- **G&A Expenses**: $5M (Q2 2025) vs $5.8M (2024), down 14% from lower headcount and stock comp.
- **Net Loss**: $18.7M (Q2 2025) vs $21.1M (2024). Cash burn Q2: $14.1M, including $0.6M severance.
- **Cash Position**: $18.2M as of June 30, 2025. Focused on non-dilutive funding via partnerships; expects reduced cash burn as Phase II trials complete.

**【Q&A Highlights】**
- **EpCAM Indication Strategy**: Colorectal cancer (high EpCAM expression, unmet need) and cholangiocarcinoma (no 2L therapies) are top priorities. 3 CRC patients achieved -6%, -8%, -10% tumor reductions.
- **Dosing Cohorts**: Tumor reductions seen across multiple cohorts; detailed updates expected Q4 2025. Subcutaneous dosing now used to minimize toxicity.
- **Partnership Progress**: Term sheet signed for one Phase II asset; expects transaction closure Q4 2025.

BioAtla (BCAB)-7 Aug 25-2025 Q2 Earnings call transcript

- **EpCAM/CD3 Bispecific T Cell Engager**: No MTD observed; 300 μg dose cohort tolerable with tumor reductions. Mid-2025 data readout for dose escalation, H1 2026 expansion data.
- **Mec-V Survival Superiority**: 59% 2-year survival in mKRAS NSCLC vs <20% standard care; 73% 1-year survival in sarcoma patients.
- **Oz-V Breakthrough in Head & Neck Cancer**: 100% DCR, 45% ORR in heavily pretreated HPV+ patients. FDA Fast Track discussions ongoing.
- **Financial Resilience**: $32.4M cash runway to H1 2026; R&D expenses down 35% YoY through cost optimization.

**【CEO Summary Section】**
- **EpCAM/CD3 T Cell Engager Progress**: Phase 1 dose escalation study shows no maximum tolerated dose reached; 3/3 patients at 300 μg dose cohort tolerated therapy with no dose-limiting toxicities. Multiple patients achieved tumor reductions and remained on therapy for months. Mid-2025 data readout expected for 300 μg dose, with expansion cohort data in H1 2026.
- **Mec-V (CAB-AXL-ADC) Performance**: 2-year landmark survival of 59% in mKRAS NSCLC vs <20% with standard care. Sarcoma patients showed 1-year survival of 73%, highlighting potential disease modification. Phase 2 data readout anticipated in H1 2026.
- **Oz-V (CAB-ROR2-ADC) Activity**: 100% disease control rate (DCR) and 45% overall response rate (ORR) in HPV+ head and neck cancer patients with 3+ prior lines of therapy. Fast Track Designation discussions ongoing with FDA.
- **Partnership Strategy**: Focused on prioritizing ROR2 and CTLA-4 programs for external collaboration, while maintaining flexibility for potential internal advancement of Mec-V.

**【CFO Financial Commentary】**
- **Q1 2025 Financials**: R&D expenses decreased 35% YoY to $12.4M, driven by reduced Phase 2 trial costs. G&A expenses down 5% to $5.3M. Net loss narrowed to $15.3M (vs $23.2M YoY). Cash balance of $32.4M as of March 31, 2025, providing runway to H1 2026 readouts.
- **Cost Optimization**: Restructuring efforts reduced workforce-related expenses, enabling focus on high-priority programs. Expect continued expense reductions through 2025.

**【Q&A Highlights】**
- **EpCAM Dose Escalation**: 300 μg cohort data expected mid-2025; 900 μg dose exploration contingent on patient enrollment timing. CRS controlled via tocilizumab prophylaxis and minimal steroid use.
- **Mec-V Pivotal Design**: Potential randomized trial vs docetaxel in 2nd/3rd-line mKRAS NSCLC. Accelerated approval pathway under evaluation for Oz-V in HPV+ HNSCC.
- **Partnership Criteria**: Seeking deals balancing North American commercial control with upfront cash and near-term milestones. Multiple active discussions with potential collaborators.

BioAtla (BCAB)-6 May 25-2025 Q1 Earnings call transcript

- **EpCAM Breakthrough**: BA3182 shows stable disease >1 year in colorectal cancer, with 300 µg dosing on track for mid-2025 readout.
- **Mec-V Longevity**: 2-year OS 58% in KRAS+ NSCLC vs. ~30% standard care, with 2-year complete response.
- **Oz-V HPV Success**: 45% ORR in HPV+ HNSCC, 16-month complete response, targeting Phase 3 confirmation.
- **Financial Sustainability**: $49M cash, 30% workforce reduction extends runway to H1 2026.
- **Partnership Momentum**: Mid-tier pharma interest in Oz-V ($>1B peak sales), EpCAM data-driven discussions Q2 2025.


**【CEO Business Update】**
- **EpCAM T-cell Engager (BA3182)**: Dose escalation progressing well with 3 patients at 100 µg weekly, targeting 300 µg in Q2 2025. Animal models suggest tumor reduction at ≥200 µg, with data readouts expected in mid-2025 for dose escalation and H1 2026 for expansion. A colorectal cancer patient has stable disease >1 year.
- **Mec-V (CAB-AXL-ADC)**: 1.8 mg/kg Q2W cohort shows 66% 1-year OS and 58% 2-year OS in KRAS+ NSCLC, vs. 2-year OS of ~30% with standard therapy. 2-year complete response in 1 patient, 7% treatment discontinuation rate.
- **Oz-V (CAB-R2-ADC)**: 1.8 mg/kg Q2W in HPV+ HNSCC yields 45% ORR, 100% DCR, and 27% confirmed responses. 16-month complete response in 1 patient. Seeking Phase 3 confirmation with FDA.
- **Evalstotug (CAB-CTLA4)**: 64% ORR and 100% DCR in melanoma with differentiated safety (18% Grade 3 AEs vs. 40% for ipilimumab). Partnering discussions initiated.
- **Corporate Restructuring**: 30% workforce reduction to extend runway beyond H1 2026, with $0.6M one-time severance costs.

**【CFO Financial Review】**
- **Q4 2024 Results**: R&D expenses $11.6M (down 50% vs. Q4 2023), G&A $4.6M (down 22%). Net loss $14.9M vs. $26.9M. Cash balance $49M (down from $111.5M), with $72M annualized cash burn.
- **2025 Outlook**: R&D expenses to decrease further as Phase 2 trials complete, with focus on EpCAM and Oz-V.

**【Q&A Highlights】**
- **Partnership Progress**: Oz-V in advanced HNSCC discussions with mid-tier pharma ($>1B peak sales potential). EpCAM T-cell engager partnering contingent on mid-2025 data.
- **Mec-V Correlation**: >70% of KRAS+ NSCLC patients co-express AXL, with 100% G12C mutants positive. No prior PAN KRAS inhibitor exposure in trial.
- **Smoking Status**: HPV+ HNSCC patients' smoking history under analysis, but data suggests ROR2 upregulation in HPV-driven cancers independent of smoking.
- **EpCAM Expansion**: Targeting 300 µg cohort in mid-2025, with potential for higher doses if recruitment allows.


Actual	-0.9	-0.68	-0.6499	-0.77	-0.69	-0.6339	-0.58	-0.75	-0.7	-0.56	-0.48	-0.44	-0.22	-0.3	-0.26	-0.32	-0.27
Forecast	-0.8457	-0.6441	-0.6556	-0.6863	-0.8005	-0.7262	-0.6036	-0.6406	-0.7741	-0.7925	-0.5416	-0.4481	-0.4133	-0.385	-0.2933	-0.28	-0.2967
Surprise	-6.42%	-5.57%	+0.87%	-12.20%	+13.80%	+12.71%	+3.91%	-17.08%	+9.57%	+29.34%	+11.37%	+1.81%	+46.77%	+22.08%	+11.35%	-14.29%	+9.00%

Actual	250.00K	0	0	0	0	0	0	0	0	0	0	0	11.00M	0	0	0	0
Forecast	170.00K	10.98M	250.00K	333.33K	466.67K	1.50M	0	0	0	0	0	0	0	0	0	0	0
Surprise	+47.06%	-100.00%	-100.00%	-100.00%	-100.00%	-100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

BCAB

BCAB fundamentals

BCAB Q3 2025 Earnings

Earnings Call

You can ask Aime

BCAB

BCAB fundamentals

BCAB Q3 2025 Earnings

Earnings Call

BCAB Earnings Call Summary for Q3/20254:30 PM on Nov 13, 2025

BCAB Earnings Call Summary for Q2/20254:30 PM on Aug 7, 2025

BCAB Earnings Call Summary for Q1/20254:30 PM on May 6, 2025

BCAB Earnings Call Summary for Q4/20244:30 PM on Mar 27, 2025

BCAB Earnings Call Summary for Q3/20244:30 PM on Nov 7, 2024

You can ask Aime